VIOLETTE: A Study of Olaparib in Triple Negative Breast Cancer
Español  |  中國傳統的  |  简体中文
Call us  (855) 528-7322
Main Menu

VIOLETTE: A Study of Olaparib in Triple Negative Breast Cancer

Sponsor: AstraZeneca

Protocol D5336C00001: VIOLETTE is a study comparing treatment with olaparib alone versus the combinations of olaparib+AZD6738 and olaparib+AZD1775 in patients with metastatic, triple negative breast cancer that have previously been treated with a taxane and/or an anthracycline.